Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.65 |
| ▸ | LPL | P06858 | 13/20 | 0.65 |
| ▸ | F11 | P03951 | 2/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1585363 | 0.98 | LIPG (0.62) | LIPGLPLF11ESR2CA1 | |
| Hydrochloric Acid SCHEMBL101098 | 0.96 | LIPG (0.61) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL23085216 | 0.86 | LIPG (0.50) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL3128892 | 0.85 | LPL (0.71) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL10006068 | 0.83 | LIPG (0.81) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL15432466 | 0.83 | LPL (0.69) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL228212 | 0.82 | LPL (0.71) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL1331631 | 0.82 | LIPG (0.63) | LIPGLPLF11 | |
| SCHEMBL31329315 | 0.82 | LPL (0.71) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL31329303 | 0.82 | ESR2 (0.57) | LIPGLPLF11ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739345-A1 | BORONATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME | Boston Scientific Scimed, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025235782-A1 | BORONATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250345434-A1 | BORONATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250295815-A1 | PORPHYRIN-HYDROPORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF | NIRVANA SCIENCES | 2025-09-25 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-119707886-A | Preparation method of amine compound | 江苏丽源医药有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-1844019-B1 | METHODE FOR THE PRODUCTION OF LOSARTAN | RATIOPHARM GMBH (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-2080756-A2 | Method for making losartan | Ratiopharm GmbH (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20090111994-A1 | Method for The Production of Losartan | RATIOPHARM GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111994-A1 | Method for The Production of Losartan | RATIOPHARM GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147574-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006081807-A2 | METHOD FOR THE PRODUCTION OF LOSARTAN | RATIOPHARM GMBH (DE) | 2006-08-10 | — | — | WO | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345434-A1 | BORONATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME | BCCIP, BLM, BTD | LIPG 432/4885LPL 3023/4885F11 1935/4885 |
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | LIPG 82/4885LPL 1248/4885F11 225/4885 |
| US-20090111994-A1 | Method for The Production of Losartan | AGTR1, REN, AGTR2 | LIPG 1081/4885LPL 820/4885F11 2116/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | LIPG 3210/4885LPL 3232/4885F11 1542/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | LIPG 249/4885LPL 178/4885F11 1186/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LIPG 3843/4885LPL 4440/4885F11 357/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | LIPG 2261/4885LPL 3327/4885F11 4354/4885 |
| US-20250295815-A1 | PORPHYRIN-HYDROPORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF | PPOX, PPIF, HMBS | LIPG 3498/4885LPL 3774/4885F11 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.